Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2021 > Vol 2, №8 (2021) > Topical issues of differential diagnosis and treatment of cough during the pandemic

Topical issues of differential diagnosis and treatment of cough during the pandemic

Elena N. Popova

For citation:


  • Abstract
  • About the Author
  • References

Abstract

A cough is observed by medical practitioners of various specialties, and is among the most common symptoms of the broad range of disorders. The cause of coughing remains unclear in more than half of adults, who visit physicians with complaints of respiratory symptoms. The paper reports the principles of the cough differential diagnosis and treatment in patients with respiratory disorders, including during the pandemic; the cough features, characteristic of pulmonary fibrosis and COVID-19, are discussed. The clinical case of the 47-year-old patient, illustrating the need to use CT not only at onset, during the acute period of the disease, but also during the recovery period in patients with a lingering cough, is discussed as an example of the cough differential diagnosis.

Key words: COVID-19, cough, post-COVID syndrome, pulmonary fibrosis, differential diagnosis of cough.

About the Author

Elena N. Popova 1

1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

References

1.    Chuchalin A.G. Abrosimov V.N. Kashel'. Moscow: GEOTAR-Media, 2016. ISBN 978-5-9704-3728-5. URL: https://www.rosmedlib.ru/book/ISBN9785970437285.html (in Russian).

2.   Braman SS. Postinfectious cough: ACCP evidencebased clinical practice guidelines. Chest 2006; 129 (Suppl. ): 138S–147S.

3.   Morice AH, McGarvey L, Pavord I. Recommendations for the management of cough in adults. Thorax 2006; 61 (Suppl. 1): 1–24.

4.   Madison JM, Irwin RS. Cough. Comprehensive respiratory medicine. Ed. R. Albert, S. Spiro, J. Jett. 2nd ed. London: Harcourt Publishers Limitel, 2001. P. 15.1–15.6.

5.   Morice AH, Fontana GA, Belvisi MG et al. ERS guidelines on the assessment of cough. Eur Respir J 2007; 29: 1256–76.

6.    Rukovodstva dlia vrachei obshchei praktiki (semeinykh vrachei). Kashel'. Moscow, 2015 (in Russian).

7.   Wiersinga WJ, Rhodes A, Cheng AC et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020; 324 (8): 782–93. DOI: 10.1001/jama.2020.12839. PMID: 32648899.

8.   Garg D, Srivastava AK, Dhamija RK. Beyond Fever, Cough and Dyspnea: The Neurology of COVID-19. J Assoc Physicians India 2020; 68 (9): 62–6. PMID: 32798347.

9.   Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci 2020; 41 (10): 2657–69. DOI: 10.1007/s10072-020-04575-3. PMID: 32725449; PMCID: PMC7385206.

10. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (2): 271–280. DOI: 10.1016/j.cell.2020.02.052

11. Mancia G, Rea F, Ludergnani M et al. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med 2020; 382 (25): 2431–40. DOI: 10.1056/NEJMoa2006923

12. Alam SB, Willows S, Kulka M. Sandhu JK. Severe acute respiratory syndrome coronavirus 2 may be an underappreciated pathogen of the central nervous system. Eur J Neurol 2020; 15: 10.1111/ene.14442. DOI: 10.1111/ene.14442.

13. Sungnak W, Huang N, Becavin C et al. SARS‐CoV‐2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020; 26: 681–7.

14. Lechien JR, Chiesa-Estomba CM, De Siati DR et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020; 277 (8): 2251–61.

15. Pascarella G, Strumia A, Piliego C et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020; 288 (2): 192–206. DOI: 10.1111/joim.13091. PMID: 32348588; PMCID: PMC7267177.

16. Puzyrenko A, Felix JC, Ledeboer NA et al. Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis. Pathology 2021: S0031-3025 (21): 00514-6. DOI: 10.1016/j.pathol.2021.09.005. PMID: 34836647; PMCID: PMC8572726.

17. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med 2020; 8 (8): 807–15. DOI: 10.1016/S2213-2600(20)30225-3. PMID: 32422178; PMCID: PMC7228727.

18. Puzyrenko A, Felix JC, Sun Y, Rui H, Sheinin Y. Acute SARS-CoV-2 pneumonitis with cytotoxic CD8 positive T-lymphocytes: case report and review of the literature. Pathol Res Pract 2021; 220: 153380.

19. Vitiello A, Pelliccia C, Ferrara F. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. SN Compr Clin Med 2020. Aug 27: 1–4. DOI: 10.1007/s42399-020-00487-7. PMID: 32875276; PMCID: PMC7452615.

20. Meyer KC. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med 2017; 11 (5): 343–59. DOI: 10.1080/17476348.2017.1312346. PMID: 28345383.

21. Wuyts WA, Wijsenbeek M, Bondue B et al. Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. Respiration 2020; 99 (1): 73–82. DOI: 10.1159/000504763. PMID: 31830755; PMCID: PMC6979429.

22.  Rachina S.A., Kozlov R.S., Tatochenko V.K. et al. Praktika lecheniia ostrykh respiratornykh infektsii u detei v ambulatornopoliklinicheskikh uchrezhdeniiakh RF: rezul'taty mnogotsentrovogo farmakoepidemiologicheskogo issledovaniia. Klinicheskaia farmakologiia i terapiia. 2016; 25 (2): 20–7 (in Russian).

23. Grigoryan L, Zoorob R, Shah J et al. Antibiotics prescribing for uncomplicated acutebronchitis is highest in younger adults. Antibiotics (Basel, Switzerland) 2017; 6 (4). PII: E22. DOI: 10.3390/antibiotics6040022

24.  Kliachkina I.L., Sinopal'nikov A.I. Ambroksol v programme lecheniia khronicheskikh bronkholegochnykh zabolevanii. Prakticheskaia pul'monologiia. 2018; 2: 83–92 (in Russian).

25. Seifart C, Clostermann U, Seifart U et al. Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicology and Applied Pharmacology 2005; 203 (1): 27–35.

26. Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183 (6): 788-824.


For citation:Popova E.N., Ponomareva L.A., Bondarenko I.B. Topical issues of differential diagnosis and treatment of cough during the pandemic. Clinical review for general practice. 2021; 8: 20–26. DOI: 10.47407/kr2021.2.8.00094


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru